We are analyzing https://link.springer.com/article/10.1007/s40120-023-00474-9.

Title:
Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients | Neurology and Therapy
Description:
Introduction Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare demyelinating disorder of the central nervous system. Despite increased recognition of MOGAD as a distinct disease and the availability of sensitive methods of MOG antibody testing, diagnostic challenges remain. We conducted a survey to explore the patient experience from the start of symptoms to final MOGAD diagnosis. Methods A 23-question online survey (including multiple-choice and free-text responses) covering symptom history, healthcare interactions and impact of diagnosis was emailed to people living with MOGAD by The MOG Project patient advocacy group. People living with MOGAD could share the survey with their caregivers. Anonymised responses were analysed. Results In total, 204 people living with MOGAD or their caregivers from 21 countries completed the survey; most respondents were from North America. Age of symptom onset ranged from 1 to 66 (median 28) years. Symptoms that prompted patients to seek medical care included blurred vision/loss of vision (58.2%), eye pain (35.8%) and difficulty walking (25.4%). Patients most frequently presented to emergency care physicians (38.7%) and primary care doctors (26.0%), with the MOGAD diagnosis most often made by general neurologists (40.4%) or neuro-immunologists (30.0%). Patients saw a median of four doctors before diagnosis, with 26.5% of patients seeing at least six doctors. Although 60.6% of patients received a MOGAD diagnosis within 6 months of experiencing initial health problems, 17.7% experienced a ≥ 5-year delay. More than half of patients (55.4%) received an alternative primary diagnosis before final MOGAD diagnosis. Most respondents (60.6%) reported receiving insufficient information/resources at the time of MOGAD diagnosis. Diagnostic delay was associated with long-term negative consequences for physical health. Conclusion This survey provides unique insights from people living with MOGAD and their caregivers that could help address the challenges faced in the pathway to final MOGAD diagnosis.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

mogad, survey, diagnosis, patients, disease, pubmed, article, google, scholar, mog, respondents, data, medical, care, doctors, study, patient, symptoms, responses, health, pathway, myelin, diagnostic, received, oligodendrocyte, glycoprotein, central, neurol, time, clinical, antibodyassociated, living, initial, table, people, rare, project, ucb, pharma, information, antibody, research, healthcare, included, primary, general, problems, reported, usa, fig,

Topics {✒️}

white matter long-term motor mog-igg cell-based assays presenting summary statistics leg/arm tingling/loss steroid-sparing maintenance immunotherapy full-length human mog included blurred vision/loss myelin oligodendrocyte glycoprotein central nervous system large multi-ethnic population reduced health-related quality article download pdf long-term negative consequences mogad-related health problems long-term neuropsychological outcomes incorporate mog-ig testing long-term disease burden cogent skills working free-text responses describing adverse long-term physical blurred vision/loss mogad-related health problem family medicine doctor/internist low-titre mog antibodies monophasic demyelinating disorders julia lefelar conceptualised julia lefelar developed identifying free-text information neurological demyelinating disorders initial health problems multi-step patient pathway privacy choices/manage cookies mog antibody assays sensitive/specific diagnostic testing cell-based assay health-related quality julia lefelar distributed nmo spectrum disorder including multiple sclerosis free-text response data acute disseminated encephalomyelitis rare demyelinating disorder including mental health disease burden prior patient advocacy group mog antibody disease mog-antibody disease acute demyelinating events psychological health outcomes

Questions {❓}

Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients
         description:Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare demyelinating disorder of the central nervous system. Despite increased recognition of MOGAD as a distinct disease and the availability of sensitive methods of MOG antibody testing, diagnostic challenges remain. We conducted a survey to explore the patient experience from the start of symptoms to final MOGAD diagnosis. A 23-question online survey (including multiple-choice and free-text responses) covering symptom history, healthcare interactions and impact of diagnosis was emailed to people living with MOGAD by The MOG Project patient advocacy group. People living with MOGAD could share the survey with their caregivers. Anonymised responses were analysed. In total, 204 people living with MOGAD or their caregivers from 21 countries completed the survey; most respondents were from North America. Age of symptom onset ranged from 1 to 66 (median 28) years. Symptoms that prompted patients to seek medical care included blurred vision/loss of vision (58.2%), eye pain (35.8%) and difficulty walking (25.4%). Patients most frequently presented to emergency care physicians (38.7%) and primary care doctors (26.0%), with the MOGAD diagnosis most often made by general neurologists (40.4%) or neuro-immunologists (30.0%). Patients saw a median of four doctors before diagnosis, with 26.5% of patients seeing at least six doctors. Although 60.6% of patients received a MOGAD diagnosis within 6 months of experiencing initial health problems, 17.7% experienced a ≥ 5-year delay. More than half of patients (55.4%) received an alternative primary diagnosis before final MOGAD diagnosis. Most respondents (60.6%) reported receiving insufficient information/resources at the time of MOGAD diagnosis. Diagnostic delay was associated with long-term negative consequences for physical health. This survey provides unique insights from people living with MOGAD and their caregivers that could help address the challenges faced in the pathway to final MOGAD diagnosis.
         datePublished:2023-04-06T00:00:00Z
         dateModified:2023-05-10T00:00:00Z
         pageStart:1081
         pageEnd:1101
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s40120-023-00474-9
         keywords:
            Demyelination
            Diagnosis
            Myelin oligodendrocyte glycoprotein (MOG)
            Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
            Neurology
            Patient perspective
            Survey
            Symptoms
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig6_HTML.png
         isPartOf:
            name:Neurology and Therapy
            issn:
               2193-6536
               2193-8253
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Healthcare
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jonathan D. Santoro
               url:http://orcid.org/0000-0002-8350-8234
               affiliation:
                     name:Keck School of Medicine of USC
                     address:
                        name:Department of Neurology, Keck School of Medicine of USC, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
                     name:Children’s Hospital Los Angeles
                     address:
                        name:Division of Neurology, Children’s Hospital Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Jennifer Gould
               affiliation:
                     name:The MOG Project
                     address:
                        name:The MOG Project, Olney, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zoya Panahloo
               affiliation:
                     name:UCB Pharma
                     address:
                        name:UCB Pharma, Slough, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ella Thompson
               affiliation:
                     name:UCB Pharma
                     address:
                        name:UCB Pharma, Slough, UK
                        type:PostalAddress
                     type:Organization
                     name:Cogent Skills
                     address:
                        name:Cogent Skills, Warrington, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Julia Lefelar
               affiliation:
                     name:The MOG Project
                     address:
                        name:The MOG Project, Olney, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jacqueline Palace
               affiliation:
                     name:University of Oxford
                     address:
                        name:Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients
      description:Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare demyelinating disorder of the central nervous system. Despite increased recognition of MOGAD as a distinct disease and the availability of sensitive methods of MOG antibody testing, diagnostic challenges remain. We conducted a survey to explore the patient experience from the start of symptoms to final MOGAD diagnosis. A 23-question online survey (including multiple-choice and free-text responses) covering symptom history, healthcare interactions and impact of diagnosis was emailed to people living with MOGAD by The MOG Project patient advocacy group. People living with MOGAD could share the survey with their caregivers. Anonymised responses were analysed. In total, 204 people living with MOGAD or their caregivers from 21 countries completed the survey; most respondents were from North America. Age of symptom onset ranged from 1 to 66 (median 28) years. Symptoms that prompted patients to seek medical care included blurred vision/loss of vision (58.2%), eye pain (35.8%) and difficulty walking (25.4%). Patients most frequently presented to emergency care physicians (38.7%) and primary care doctors (26.0%), with the MOGAD diagnosis most often made by general neurologists (40.4%) or neuro-immunologists (30.0%). Patients saw a median of four doctors before diagnosis, with 26.5% of patients seeing at least six doctors. Although 60.6% of patients received a MOGAD diagnosis within 6 months of experiencing initial health problems, 17.7% experienced a ≥ 5-year delay. More than half of patients (55.4%) received an alternative primary diagnosis before final MOGAD diagnosis. Most respondents (60.6%) reported receiving insufficient information/resources at the time of MOGAD diagnosis. Diagnostic delay was associated with long-term negative consequences for physical health. This survey provides unique insights from people living with MOGAD and their caregivers that could help address the challenges faced in the pathway to final MOGAD diagnosis.
      datePublished:2023-04-06T00:00:00Z
      dateModified:2023-05-10T00:00:00Z
      pageStart:1081
      pageEnd:1101
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s40120-023-00474-9
      keywords:
         Demyelination
         Diagnosis
         Myelin oligodendrocyte glycoprotein (MOG)
         Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
         Neurology
         Patient perspective
         Survey
         Symptoms
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40120-023-00474-9/MediaObjects/40120_2023_474_Fig6_HTML.png
      isPartOf:
         name:Neurology and Therapy
         issn:
            2193-6536
            2193-8253
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Healthcare
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jonathan D. Santoro
            url:http://orcid.org/0000-0002-8350-8234
            affiliation:
                  name:Keck School of Medicine of USC
                  address:
                     name:Department of Neurology, Keck School of Medicine of USC, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
                  name:Children’s Hospital Los Angeles
                  address:
                     name:Division of Neurology, Children’s Hospital Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Jennifer Gould
            affiliation:
                  name:The MOG Project
                  address:
                     name:The MOG Project, Olney, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zoya Panahloo
            affiliation:
                  name:UCB Pharma
                  address:
                     name:UCB Pharma, Slough, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ella Thompson
            affiliation:
                  name:UCB Pharma
                  address:
                     name:UCB Pharma, Slough, UK
                     type:PostalAddress
                  type:Organization
                  name:Cogent Skills
                  address:
                     name:Cogent Skills, Warrington, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Julia Lefelar
            affiliation:
                  name:The MOG Project
                  address:
                     name:The MOG Project, Olney, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jacqueline Palace
            affiliation:
                  name:University of Oxford
                  address:
                     name:Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Neurology and Therapy
      issn:
         2193-6536
         2193-8253
      volumeNumber:12
Organization:
      name:Springer Healthcare
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Keck School of Medicine of USC
      address:
         name:Department of Neurology, Keck School of Medicine of USC, Los Angeles, USA
         type:PostalAddress
      name:Children’s Hospital Los Angeles
      address:
         name:Division of Neurology, Children’s Hospital Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:The MOG Project
      address:
         name:The MOG Project, Olney, USA
         type:PostalAddress
      name:UCB Pharma
      address:
         name:UCB Pharma, Slough, UK
         type:PostalAddress
      name:UCB Pharma
      address:
         name:UCB Pharma, Slough, UK
         type:PostalAddress
      name:Cogent Skills
      address:
         name:Cogent Skills, Warrington, UK
         type:PostalAddress
      name:The MOG Project
      address:
         name:The MOG Project, Olney, USA
         type:PostalAddress
      name:University of Oxford
      address:
         name:Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jonathan D. Santoro
      url:http://orcid.org/0000-0002-8350-8234
      affiliation:
            name:Keck School of Medicine of USC
            address:
               name:Department of Neurology, Keck School of Medicine of USC, Los Angeles, USA
               type:PostalAddress
            type:Organization
            name:Children’s Hospital Los Angeles
            address:
               name:Division of Neurology, Children’s Hospital Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Jennifer Gould
      affiliation:
            name:The MOG Project
            address:
               name:The MOG Project, Olney, USA
               type:PostalAddress
            type:Organization
      name:Zoya Panahloo
      affiliation:
            name:UCB Pharma
            address:
               name:UCB Pharma, Slough, UK
               type:PostalAddress
            type:Organization
      name:Ella Thompson
      affiliation:
            name:UCB Pharma
            address:
               name:UCB Pharma, Slough, UK
               type:PostalAddress
            type:Organization
            name:Cogent Skills
            address:
               name:Cogent Skills, Warrington, UK
               type:PostalAddress
            type:Organization
      name:Julia Lefelar
      affiliation:
            name:The MOG Project
            address:
               name:The MOG Project, Olney, USA
               type:PostalAddress
            type:Organization
      name:Jacqueline Palace
      affiliation:
            name:University of Oxford
            address:
               name:Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Neurology, Keck School of Medicine of USC, Los Angeles, USA
      name:Division of Neurology, Children’s Hospital Los Angeles, Los Angeles, USA
      name:The MOG Project, Olney, USA
      name:UCB Pharma, Slough, UK
      name:UCB Pharma, Slough, UK
      name:Cogent Skills, Warrington, UK
      name:The MOG Project, Olney, USA
      name:Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

External Links {🔗}(169)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.42s.

LINK . SPRINGER . COM {}